RE:RE:NMIBC Ph. 2b will include multiple doses + CLT"
The market isn't as sophisticated as some here pretend. All it knows is black & white, works or doesn't.""" Absolutely right!! Can easily be manipulated as has been shown by our 22 pennies!! Can pharma be manipulated, fooled , see only black and white??? HELL NO!! They see increments, shadows of success, build on tiny improvements, that is what science and research is all about, building on progress and innovation! Now has TLT done anything innovative, a success to build on, some monor thing that no one was expecting??? Hmmmmm, Avboy, u got any clues to this poser??? Yaz, anything we did over the last 12 months that was different, out of the ordinary????! LIKE MAKE THREE PATIENTS, THAT ALL PHARMA HAD GIVEN UP ON, cancer free for over 90 days and their cancer progression in the cancer atea had stopped for over 180 days, and that had been done with one easy, no side affects treatment, naw, i dont see anything new, important, different, able to ise for future research, results like no other pharma has accomplished, nah!! Nothing there to get pharma excited about, nothing there to build on, bupkiss is what everyone wants us to believe!!! REALLY, UR FUKKING KIDDING ME RIGHT!! U GUYS ACTUALLY BELIEVE THAT IS JUST HO HUM RESULTS????? IF U DO!!! UR DEFINITELY A TRUMP SUPPORTER AND U TAKE TOOK THE SHORT BUS TO SCHOOL !! bionicjoe wrote: High-dose 6-month cystoscopy, if it fails to prevent recurrence, will nontheless allow a move to Ph. 2.b
As already identified in the Nov. 8 press release, to spike the immune system, Ph. 2b will include multiple doses during days 90 and 180. We know that they should also integrate CLT pre-treatments (CLT is already approved for treatment, requiring no approval, as per TLT if I recall corrrectly (need to verify that though)). And possibly anti-vaccine, if time/approval are on our side.
Allow is not the issue. HC could very well allow TLT to hold a phase 2 trial but who would be willing to pay for it knowing the majority of patients failed to pass their 180 day efficacy tests? This is all about efficacy or in plain language, the science must work as explained to shareholders in the company presentations.They've already downsized its role from treating visible tumors to mopping up duty after a standard of care procedure is tried first and now you want to water down its job even ld have been simpler? Because RW knows it is difficult to convince capital market investors to pay for a phase 2 without some evidence of efficacy to pump up the interest.